Net Loss Per Share Attributable to Ordinary Shareholders (Tables) - Chemomab Therapeutics Ltd [Member]

6 Months Ended

12 Months Ended

Jun. 30, 2026

Dec. 31, 2025

Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Ordinary Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:


		Six Months ended				Three Months ended				Six Months ended				Three Months ended
		June 30, 2026				June 30, 2026				June 30, 2025				June 30, 2025
Numerator:
Net loss			3,938				2,165				5,380				2,057

Denominator:
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted			639,483,242				640,243,933				459,829,621				463,508,519

Net loss per share attributable to ordinary shareholders, basic and diluted			0.006				0.003				0.012				0.004

The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:

		Year ended				Year ended				Year ended
		December 31,				December 31,				December 31,
		2025				2024				2023
		In USD thousands, except share and per share data
Numerator:
Net loss			8,995				13,945				24,221

Denominator:
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted			510,227,715				359,048,638				234,998,859

Net loss per share attributable to ordinary shareholders, basic and diluted			0.018				0.039				0.103

Schedule of Ordinary Shares that were Excluded from the Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders

The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:

Six Months ended

June 30,

Six Months ended

June 30,

2026

2025

Outstanding options to purchase ordinary shares and RSAs

40,589,680

44,471,160

The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:

		Year ended				Year ended				Year ended
		December 31,				December 31,				December 31,
		2025				2024				2023
		Number of shares

Outstanding options to purchase ordinary shares and RSAs			41,564,080				38,494,200				29,873,100